Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 154

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 154
---
. (a Fortress partner company). Since August 2022, Mr. Jin has served as Treasurer of Fortress’
private subsidiaries, including Cyprium Therapeutics, Urica Therapeutics, Helocyte, and Cellvation. From March 2022 to August 2022,
he served as Interim Chief Executive Officer at Avenue Therapeutics Inc. Prior to joining Fortress, Mr. Jin was a member of
the Private Equity group at Barings focused on control equity and asset-based investments in pharma and biotech. Prior to that, he was
Director of Corporate Development at Sorrento Therapeutics, and Vice President of Healthcare Investment Banking at FBR & Co.
Mr. Jin began his career in management consulting at IMS Health (now IQVIA). Mr. Jin has a Bachelor of Science degree in Industrial
Engineering & Management Sciences with a double-major in Mathematical Methods in the Social Sciences from Northwestern University.
Based on Mr. Jin’s financial experience and knowledge of the biotechnology industry, we believe that Mr. Jin has the appropriate
set of skills to serve as a member of the board of directors.

Lindsay A. Rosenwald, M.D. – Director

Dr. Rosenwald has served as a member of our Board
since our inception. Dr. Rosenwald has been a member of the Board of Directors of Fortress Biotech, Inc. since October 2009 and
has served as its Chairman, President and Chief Executive Officer since December 2013. From November 2014 to August 2015, Dr. Rosenwald
served as Interim President and CEO of Checkpoint Therapeutics, Inc. and remains on that company’s board of directors. He
also serves on the board of directors of Avenue Therapeutics, Inc. and Journey Medical Corporation. Prior to that, from 1991 to
2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 30 years, Dr. Rosenwald has acted as a biotechnology entrepreneur
and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr.
Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine. We believe
that Dr. Rosenwald’s extensive biotechnology, pharmaceutical and finance expertise, as well as his medical background and in-depth
understanding of our businesses, makes him an exemplary candidate to continue serving on our Board.

Michael J. Zelefsky,